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BACKGROUND: Despite programmed screening in the Netherlands, the decrease in incidence of cervical carcinoma lags behind.
We analysed screening results preceding carcinoma cases, timeliness in case of follow-up, and FIGO (International Federation of
Gynaecology and Obstetrics) stages as efficiency parameters for screening were taken.
METHODS: We analysed 286 women with cervical cancer between 2005 and 2007 for cytology history preceding carcinoma,
hierarchically arranging cytology history (if present) into three groups: ‘screened’, ‘work-up’, and ‘underscreened’ (46 yrs before
diagnosis). For screen- and work-up smears, we analysed timeliness. FIGO stage was measured in relation to cytology history.
RESULTS: A total of 105 out of 286 (36.7%) women with cervical carcinoma were screened preceding the diagnosis. Delayed time
intervals in case of abnormal cytology were 43.5% for borderline/mild dyskaryosis (BMD) and 38.0% for BMD (moderate dyskaryosis
or worse; P¼ 0.51). A total of 108 out of 286 (36.4%) women were underscreened, and 73 out of 286 (25.5%) were unscreened.
Advanced carcinoma or FIGO stage X2B in screened women was 16.0 vs 48.7% in work-up, underscreened, or unscreened
(Po0.001).
CONCLUSION: Women with cervical cancer are underscreened and have poor timeliness in case of abnormal cytology. Being un- or
underscreened correlates significantly with higher cervical cancer stages, especially in older women (aged X49 years; Po0.001).
Improvement of attendancy is needed to meet the standard of quality for screening programmes.
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Cervical cancer is preceded by well-defined premalignant
lesions, which can be identified by detecting abnormal cells in
Papanicolaou smear. Cervical screening by cytology with adequate
treatment have resulted in a decrease in incidence and mortality of
cervical carcinoma (Gustafsson et al, 1997; Vizcaino et al, 2000).
In the Dutch screening programme, women aged 30–60 years
are invited every 5 years for seven times in a lifetime. Modelling,
before the introduction of the Dutch cervical screening pro-
gramme, predicted a decrease in cervical carcinoma by approxi-
mately 75%, assuming full coverage (van Ballegooijen, 1998) within
the range mentioned in other studies (Sasieni and Adams, 1999;
IARC, 2005).
Coverage of the screening programme is currently 77% (Rebolj
et al, 2007). Approximately 65% of women attend the screening
programme after an invitation, referred to as smears made inside
the screening programme and 12% reflects smears made outside
the screening programme (opportunistic smears). Approximately
23% of the invited women will not be screened at all (Bais et al,
2007). Collectively, the effect on carcinoma incidence through
these two modes of screening will be lower than modelled for the
programme, as full coverage is not attained. Moreover, the non-
participating fraction of women (referred to as non-attendees) has
a higher risk for cervical carcinoma than average, thus further
decreasing the effectiveness of a programme in reducing carci-
noma incidence (van Oortmarssen and Habbema, 1991). Earlier
studies have shown that 40–50% of the women diagnosed with
cervical cancer are in the non-compliance group (van der Graaf
et al, 1986; Bos et al, 2006).
Here we analysed 286 women, with cervical carcinoma from
the region Noord-Holland/Flevoland in the Netherlands, diagnosed
between 2005 and 2007. We analysed the relationship between the
FIGO (International Federation of Gynaecology and Obstetrics)
stage of the detected carcinoma and the associated screen status. In
addition, we analysed whether the smear was made within or
outside the screening programme, and the compliance for referral
to the gynaecologist in case of an abnormal smear.
MATERIALS AND METHODS
Data of regional carcinoma cases obtained from PALGA
All cytological and histological results carried out in the Netherlands
are excerpted in the Pathological National Automated Archive
(PALGA), a centralised database. Since 1991, coverage is at least
95% (Casparie et al, 2007). We linked patient records based on the
identity of the encrypted first four letters of the maiden name and
date of birth. The ‘twinning rate’ is estimated to be around 2% per
record (Bos et al, 2002).
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In total, our query in PALGA provided 337 830 smears of which
334 cases (0.10%) with index-diagnosis histologically confirmed
cervical carcinoma in 2005–2007 and living in one region of
the Netherlands. Group of records, presumably belonging to a
single person, were ‘eyeballed’ (checking every case manually) to
filter out administrative twins by checking domicile, initials,
and apparent inconsistencies in clinical history (n¼ 48). This left
307 298 numbers of smears of which 286 (0.09%) women were
diagnosed with histologically confirmed cervical carcinoma.
Cervical smears were registered as either inside- or outside the
screening programme. This study was approved by the ethical
committee of PALGA.
Definition of ‘cytology history’ in this analysis
Screening histories of the 286 cases of carcinoma from PALGA
database were analysed for presence or absence of cytology
history. For each woman, we took time point with cervical
carcinoma diagnosis (t¼ 0). From this point, we did a retro-
spective research in the preceding time period to determine their
last cytological examination. Three time frames were defined as
follows: ‘unscreened’ (no smear at all before the diagnosis of
cervical carcinoma or only work-up smear before the diagnosis),
‘underscreened’ (last smear taken 46 years before the diagnosis:
the work-up smear not included), or ‘screened’ (smear taken
between 1 and p6 years before the diagnosis). We defined
cytology obtained less than 1 year preceding the diagnosis as a
‘work-up smear’.
The choice of this time period is based on the ‘once in every
5-years invitation’ of the Dutch screening programme protocol,
which means that all women between 30 and 60 years of age are
invited for programmed screening for every 5 years, which is sent
for free of charge for cytology analysis. In relation to this interval,
we have defined in our analyses the screening episode with an
interval period of 6 years before the diagnosis of cancer until 1 year
before the diagnosis. If a smear is detected in the database within
this period, we consider the women ‘screened’. Our three defined
time frames were categorised hierarchically: first, a woman was
considered ‘screened’ if she had a smear taken in this between 1
and p6 year period. Second, a woman was considered ‘un-
derscreened’ if she had a smear46 years before the diagnosis, but
not in the screened period. Third, a woman was considered
‘unscreened’ if she had only a work-up smear or had no smear at
all in the past. Owing to this hierarchical categorisation, the
women with a smear in the screened period could also have smears
in the period 46 years before the diagnosis, and/or a work-up
smear. Furthermore, women categorised as underscreened could
also have work-up smear.
Age stratification was carried out in seven groups of 5 years:
29–33, 34–38, 39–43, 44–48, 49–53, 54–58, 59–63 years of age;
in addition, o29 years and 463 years of age. Sub-analysis of
smears was based on the mode (i.e., invitational or inside the
screening programme or outside the screening programme). For this
sub-analysis of ‘within the screening programme’, we have chosen
the upper age as 63 years, as the Dutch screening programme invites
women up to age 60 years (with a cutoff at 63 years because of a
possible follow-up time) and for lower age as 29 years, as women can
be invited from the age of 29 years onwards. The number of eligible
women (29–63 years) was 217 for this sub-analysis with respect to
the the screening programme (Figure 1).
In case of multiple abnormal smears in the screening history
(e.g., in case of repeat cytology after BMD), we accepted the first
abnormal smear as the starting point. If women had only multiple
normal smear results in the screened period, we analysed the
time interval between the last smear before the diagnosis and at the
time of diagnosis. All analyses were performed using SPSS 15.0
software (IBM Company, Armonk, NY, USA).
Definition of work-up smear in this analysis
Work-up smears for diagnosis were defined as all cases of cytology
obtained o1 year before the diagnosis rather than 6 months,
because we considered women with a XBMD preceded by BMD
cytology in the period from 12 to 6 months before the diagnosis to
Aged >63 years
n = 63 / 286 (22.0%)
CxCa
n = 286
Aged <29 years
n = 6 / 286 (2.1%)
Aged 29–63 years
n = 217 / 286 (75.9%)
Last smear <1 year
n = 5
Screening programme
n = 106
Outside screening
programme
n = 74
No smear in the past
n = 35 / 63 (57.1%)
Last smear <1 year
n = 29
Last smear between >1
and <6 years
n = 75
Last smear between >1
and <6 years
n = 24
Last smear >6 years
n = 2
Last smear <1 year
n = 49
Last smear >6 years
n = 1
Last smear <1 year
n = 21
Last smear between >1
and <6 years
n = 6
Last smear >6 years
n = 1
No smear in the past
n = 37 / 217 (17.1%)No smear in the pastn = 1 / 6 (16.7%)
n = 180 n = 28n = 5
Figure 1 Flowchart of women with cervical carcinoma (stratified by three age groups, mode of screening, and cytology history). The flowchart is based on
non-hierarchical categorisation of the cytology history.
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represent women who should have had a severe abnormality in the
first smear, and thus be representative for women with signs and
symptoms of carcinoma. We have taken this into account plus
allowing a few months delay in repeat. Thus, we end the period for
work-up smears at 1 year before the diagnosis.
Screening programme in the Netherlands and eligibility
Women are invited in the Netherlands into the programme in the
year they turn 30 years of age. Actually, at the time of screening
they may still be 29 years. Similarly, at the second invitation,
women may be still 34 years of age.
Women with a normal smear results will be invited again for the
next screening round. Women with borderline/mild dyskaryosis
(BMD) are advised to repeat the smear after 6 and 18 months. If at
least one of the repeated cytology smears is read as BMD or worse,
the woman will be referred to a gynaecologist for colposcopy.
Women with4BMD (moderate dyskaryosis or worse) are referred
immediately to a gynaecologist. Women with inadequate smears
(not suitable for diagnosis) are advised to repeat the test after 6
weeks.
Time interval between abnormal smear and diagnosis of
cervical carcinoma
Among the women with cervical carcinoma, we analysed the time
interval between the first abnormal smear cytology and the
histologically confirmed diagnosis. For timeliness, women were
categorised as ‘not delayed’ or ‘delay in diagnosis’ (see Table 1 for
definitions of time frames). Smears with BMD that led to the
histologically confirmed diagnosis p24 months were considered
as ‘not delayed’. For smears with 4BMD, timeliness was set at
p6 months as described by Bos et al (2006). For time-interval
computations, all women with a smear taken up to 6 years (2192
days) before the diagnosis were included in these analyses (thus
encompassing both the screened group as the work-up group,
n¼ 195). Two cases with inadequate smears without follow-up
were excluded, leaving a total of 193 cases. After tabulating smear
results, the time interval was categorised in two periods that is, not
delayed and delay in diagnosis.
FIGO stage of cervical carcinoma related to cytology
history and mode of screening
The FIGO stage of cervical carcinoma was related to the cytology
history (i.e., presence or absence of a smear). Absence was defined
as having no smear in the screened period. Furthermore, we also
analysed the FIGO stage in relation to the cytology result of women
with a smear taken in the screened period, allowing insight in
whether an inadequate cytology advice results in a later detection
of carcinoma. Both types of analyses were stratified by age
eligibility for screening invitation, or other ages. These analyses
were also stratified by age (Figure 2). The analyses were carried out
with the Fisher’s exact test.
RESULTS
Cases of cervical carcinoma
The final query result from PALGA for the period from 2005 to
2007 provided 286 cases after excluding 48 cases because of
double-counting twinning, too late a diagnosis (i.e., in 2008),
carcinoma of endometrial origin or metastasis. Age ranged
between 25 and 93 years old (mean age, 50.8 years). We divided
the remaining 286 women into an eligible group (n¼ 217, aged
29–63) for receiving an invitation within the context of a screening
programme and a non-eligible group (i.e., aged o29 (n¼ 6), or
463 years (n¼ 63) for falling outside invitational cohorts. The
number of women without any smear in the period preceding the
diagnosis was 1 out of 6 (16.7%), 37 out of 217 (17.1%), and 35 out
of 63 (55.6%) for women aged 29, 29–63, and 463 years,
respectively (n¼ 217; Figure 1).
Cytology preceding carcinoma cases: un(der)screened,
screened, or work-up smears
The hierarchically categorised Table 2 shows that the number of
women in the screened period is 105 out of 286 (36.7%). In
addition, 18 out of 286 women (6.3%) were underscreened (i.e., no
smear between 1 and p6 years). Furthermore, 90 out of 286
women (31.5%) only had a work-up smear, and 73 out of 286
women (25.5%) had no smear at all before the histologically
confirmed diagnosis. The latter two sets represent the group of
unscreened women. As can be seen in the one, but in the lowest
row of Table 2, a sub-analysis for women eligible for screening
programme invitation, showed that 180 out of 217 (99þ 16þ 65)
women (82.9%) had at least a smear anytime preceding the
diagnosis. This percentage was composed of 45.6% for ‘screened’,
and 37.3% (7.4%þ 30.0%) for ‘underscreened’ and work-up smear.
A total of 37 out of 217 (17.1%) were ‘unscreened’, and had also no
work-up smear before the diagnosis.
Cytology results in relation to cytology history
Table 3 shows the cytology result of historical smears. Interest-
ingly, 69 of 105 women (63.8%) who were screened between 1 and
p6 years had a normal or inadequate (n¼ 2) cytology, respec-
tively. Furthermore, 15 out of 105 (14.3%) had4BMD, but cervical
cancer was diagnosed more than a year later, suggestive of time
delays. For women with only a work-up smear preceding the
diagnosis, the results show a different pattern: 4BMD was found
in 75 out of 90 women (83.3%). The results of cytology in the
group of women screened 46 years before the diagnosis
resembled the first group: 12 out of 18 women (66.7%) had a
normal cytology result, 5 out of 18 women (27.8%) had BMD
cytology result, and only 1 out of 18 (5.6%) had4BMD (Table 3).
In addition, we have sub-divided our group of underscreened
women (n¼ 18), with respect to the time interval between the last
negative smear and the diagnosis of carcinoma, into a subgroup
with the last smear made 7–11 years previously for diagnosis and a
group with the last smear made X11 years before diagnosis. We
could not find a significant difference in cytology result. However,
it should be realised that the number of women in the subgroups
was very small for a meaningful analysis (data not shown).
Table 1 Overview of the definitions in this manuscript: screen smear
(screening episode), work-up smear, and delay in diagnosis and screening
interval
Definition Description
Screen smear Smear taken between 1 and p6 years
preceding the diagnosis
Work-up smear Smear taken maximum at 1 year preceding the
diagnosis
Screening interval
in Dutch programme
Once in every 5 years (between 30 and 60 years)
‘Delay’ in diagnosis Interval between last smear and diagnosis
Delay for BMD Cytology418 months preceding the diagnosis
Delay for worse than BMD
(4BMD)
Cytology46 months preceding the diagnosis
Abbreviation: BMD¼ borderline/mild dyskaryosis.
Cytology preceding carcinoma cases
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Diagnosis of work-up smear in women with normal
cytology results in the screened period
The normal (n¼ 67) and inadequate (n¼ 2) cytology results of
women in the screened period, as shown in Table 3, does not
exclude the possibility that these women had a work-up smear as
well (as our analysis is hierarchical). Of the 69 women,
41 subsequently had 4BMD (including the two women with
inadequate cytology smear; 59.4%) and 9 had BMD (13.0%) as
work-up smear. Furthermore, 2 out of 69 (2.9%) and 1 out of 69
(1.4%) had normal cytology or inadequate cytology, respectively.
The remaining 16 out of 69 women (23.2%) had no work-up smear.
When further dividing these 53 work-up smears by the mode of
screening (‘within screening programme’ and ‘outside screening
programme’), the mode was not significantly different: 26 out of 53
women (49.1%) with a work-up smear were found within screening
programme vs 27 out of 53 (50.9%) outside the programme.
In addition, we analysed possible work-up smears from women
with4BMD and BMD in the screened period. A total of 12 out of
15 women (80.0%) with 4BMD in the screened period again had
4BMD, one woman (6.7%) had BMD, and two women (13.3%)
had no smear in the work-up for diagnosis period (not shown).
Similarly, for women with BMD in the screened period, 13 out of
21 (61.9%) had 4BMD, 3 out of 21 (14.3%) had BMD, 1 woman
(4.8%) had a normal cytology result, and 4 women (19.0%) had no
smear in the work-up period. Again, the distribution of the
indication smear is equal for both the groups (data not shown).
Screen and work-up smears in women with carcinoma in
relation to mode of screening
For the sub-analysis of cytology history in relation to the mode of
screening (stratified by age cohort), only women eligible (n¼ 217)
for programmed screening (aged 29–63 years) and having at least
one smear p6 years before diagnosis (either screen smear or
work-up smear; for definitions see Table 1) were selected (Table 4).
Screen and work-up smears are denoted separately. In addition, 14
out of 18 women (77.8%) who were categorised as underscreened
also had a work-up smear and were therefore included. The
remaining four women from this group were added to the 73
Table 2 The cytology history (hierarchical categorised into smear taken between 1 and 6 years, smear46 years, and o1 year or no smear) of women
with histologically confirmed cervical cancer diagnosis between 2005 and 2007, stratified by age cohort
Screen smear
(i.e., between 1 and 6 years) Smear taken 46 years Smear taken o1 yeara No smear Total
Age cohort N (% of row totals) N (% of row totals) N (% of row totals) N (% of row totals) N (% of row totals)
p28 years — — 5 (83.3) 1 (16.7) 6 (2.1)
29–33 years 6 (30.0) — 11 (55.0) 3 (15.0) 20 (7.0)
34–38 years 23 (56.1) — 12 (29.3) 6 (14.6) 41 (14.3)
39–43 years 28 (54.9) 5 (9.8) 10 (19.6) 8 (15.7) 51 (17.8)
44–48 years 14 (43.8) 3 (9.4) 11 (34.4) 4 (12.5) 32 (11.2)
49–53 years 11 (32.4) 3 (8.8) 11 (32.3) 9 (26.5) 34 (11.9)
54–58 years 9 (42.9) 4 (19.0) 6 (28.6) 2 (9.5) 21 (7.3)
59–63 years 8 (44.4) 1 (5.6) 4 (22.2) 5 (27.8) 18 (6.3)
X64 years 6 (9.5) 2 (3.2) 20 (31.7) 35 (55.6) 63 (22.0)
Total (aged 29–63 years)b 99 (45.6) 16 (7.4) 65 (30.0) 37 (17.1) 217 (100)
Total 105 (36.7) 18 (6.3) 90 (31.5) 73 (25.5) 286 (100)
aSmear taken o1 year before the diagnosis is considered as work-up smear for diagnosis. bWomen ageing 29–63 years with non-attendancy possibility in the previous
programmed screening round.
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Figure 2 Women with histologically confirmed cervical carcinoma; the FIGO stage in relation to their screen smear, stratified by age cohort. Each age
cohort contains two columns out of which the left column presents women without a smear in the screened period (1 andp6 years preceding diagnosis),
and the right column presents smear taken within this period.
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women without any smear before the diagnosis, as a work-up
smear was lacking.
Only 99 of 217 women (45.6%) actually had a smear taken in the
screened period (Po0.001), of whom 75 out of 99 (75.8%) had a
programmed smear and 24 out of 99 (24.2%) had the smear taken
outside the screening programme, which was statistically sig-
nificant (Po0.001).
A further 78 out of 217 (35.9%) women had a work-up smear
only, divided between 29 out of 78 (37.2%) (aged 29–63 years) for
invitational cytology and 49 out of 78 (62.8%) outside the
screening programme (Table 4 and Figure 1). In total, 40 out of
217 (18.4%) women had no smear at all p6 years before the
diagnosis.
Timeliness between first abnormal cytology smear and
histologically confirmed carcinoma
Table 5 shows the timeliness between the first abnormal smear and
histologically confirmed cervical cancer between 2005 and 2007
(stratified by cytology result: 4BMD or BMD). We included all
cytology analysis results taken up to 6 years before the diagnosis
(thus both screen smear as well as work-up smear), which resulted
in total 142 4BMD and 46 BMD cases. As shown previously,
Table 3 shows that 15 and 21 women with cytology in the screened
period had 4BMD and BMD, respectively. Furthermore, cases
with XBMD work-up smear of women, who had a normal or
inadequate cytology smear in the screened period before diagnosis,
were included (41 and 9 out of 69 women had 4BMD and BMD,
respectively).
For timeliness, we divided the interval as ‘not delayed’ and
‘delay in diagnosis’ (see Materials and methods for definitions). In
the group of women with 4BMD cytology smear, 88 out of 142
(62.0%; 95% CI: 53.5–70.0) showed no delay for diagnosis. In the
group, women with BMD, 26 out of 46 (56.5%; 95% CI: 41.1–71.1)
had no delay in diagnosis. Delay in diagnosis for women with
4BMD and BMD were observed in 54 out of 142 (38.0%) and
20 out of 46 (43.5%) women, respectively. Overall, 60.6% of
the women had no delay in diagnosis (95% CI: 53.3–67.7). The
difference in delay in diagnosis of between women with 4BMD
and BMD cytology smears was not significantly lower (P¼ 0.51).
We also analysed the work-up smears of women who had a
normal smear (12 out of 18 women; 66.7%) in the period46 years
before the diagnosis. In total, 10 of these 12 women had 4BMD
(83.3%) and 2 out of 12 women (16.7%) had again normal cytology
result. A total of 6 out of 18 women with XBMD result (one
woman with 4BMD and five women with BMD) 46 years before
diagnosis were categorised as delay in diagnosis. Together, with
the 75 women with 4BMD and 11 women with BMD, the total
Table 4 Screening mode of screen smear (i.e., between 1 and 6 years before the diagnosis) or work-up smear (o1 year before the diagnosis) sub-divided
into age cohorts of all 286 cervical carcinoma cases
Screen smear (i.e., between 1
and 6 years before the diagnosis)
Work- up smear (i.e., o1 year
before the diagnosis)a
Screening
programme
Outside screening
programme
Screening
programme
Outside screening
programme
Cytology 46 years or no cytology
preceding the diagnosis
Total
Number
(% of row totals)
Number
(% of row totals)
Number
(% of row total)
Number (% of
column total)
p28 years — — — 5 (83.3) 1 (16.7) 6 (2.1)
Age 29–33 years 5 (25.0) 1 (5.0) 8 (40.0) 3 (15.0) 3 (15.0) 20 (7.0)
Age 34–38 years 19 (46.3) 4 (9.8) 2 (4.9) 10 (24.4) 6 (14.6) 41 (14.3)
Age 39–43 years 19 (37.3) 9 (17.6) 8 (15.7) 6 (11.8) 9 (17.6) 51 (17.8)
Age 44–48 years 11 (34.3) 3 (9.4) 3 (9.4) 11 (34.4) 5 (15.6) 32 (11.2)
Age 49–53 years 7 (20.6) 4 (11.8) 3 (8.8) 11 (32.4) 9 (26.5) 34 (11.9)
Age 54–58 years 6 (28.6) 3 (14.3) 2 (19.0) 6 (28.6) 4 (19.0) 21 (7.3)
Age 59–63 years 8 (44.4) — 3 (16.7) 2 (11.1) 5 (27.8) 18 (6.3)
X64 years 2 (3.2) 4 (6.3) — 21 (33.3) 36 (57.1) 63 (22.0)
Total screening age
(29–63 years)
75 (34.6) 24 (11.1) 29 (13.4) 49 (22.6) 40 (18.4) 217 (100)
Total overall 77 (26.9) 28 (9.8) 29 (10.1) 75 (26.2) 77 (26.9) 286 (100)
The cases of women within age cohorts (29–63 years; n¼ 217) of the Dutch screening programme indicated as age strata. aThis includes women with a work-up smear, who
also had a smear taken46 years before the diagnosis but not betweenp1 and 6 years before the diagnosis: 14 out of 18 (77.8%) women who were categorised in the period
46 years before the diagnosis had a work-up smear. The remaining four women are included in the category No cytology o6 years before the diagnosis, along with women
without any smear in the past (n¼ 73), giving a total of 77.
Table 3 Screen smears, smears taken more than 6 years ago, and work-up smears in women with histologically confirmed cervical cancer diagnosis
arranged according to cytology results
Screen smear
(i.e., between 1 and 6 years) Smear taken 46 years Work-up smear (o1 year)a No smear at all Total
Cytology
Number
(% of column totals)
Number
(% of column totals)
Number
(% of column totals)
Number
(% of column totals)
Number
(% of column total)
4BMD 15 (14.3) 1 (5.6) 75 (83.3) N/A 91 (31.8)
BMD 21 (20) 5 (27.8) 11 (12.2) N/A 37 (12.9)
Normal 67 (63.8) 12 (66.7) 2 (2.2) N/A 81 (28.3)
Inadequate 2 (1.9) — 2 (2.2) N/A 4 (1.4)
No smear N/A N/A N/A 73 (100) 73 (25.5)
Total 105 (100) 18 (100) 90 (100) 73 (100) 286 (100)
Abbreviations: BMD¼ borderline/mild dyskaryosis; N/A¼ not available. aSmear taken o1 year before the diagnosis.
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4BMD and BMD cases are 142 and 46, respectively. For the
remaining 25 women, timeliness was not applicable, as they had
had either normal cytology (n¼ 23) or time information was
lacking (n¼ 2).
FIGO stage of cervical carcinoma in relation to cytology
history
In Table 6a, we show the FIGO stage in relation to the cytology
history. The FIGO stage was grouped into low (1A or 1B),
borderline (2A–2B), and high grades (X3A) because this grouping
has consequences for therapy, and gives more relevant information
about the relation between FIGO stage and screening history. FIGO
stage information was available for 90.2% (258 out of 286) of the
cases, of which 196 and 62 in the group of women aged 29–63 and
o29 and/or463 years, respectively. Most women had no cytology
smear taken in the screened period (158 out of 258; 61.2%, 95%
CI: 55.3–67.2%), leaving 100 women with a smear taken in the
screened period with a known FIGO stage in this group for
analyses. In total, 18 out of 34 women (52.9%) with FIGO stage 1A
had screen smear. Furthermore, 58 out of 95 (61.1%), 15 out of 42
(35.7%), and 3 out of 25 women (12.0%) with a screen smear
had 1B, 2A–2B, and 3A–4 FIGO stages, respectively.
When comparing the FIGO stage 1A with 1B, there is statistically
no difference (P-value, 0.424) in the percentage of screen smear.
However, when we compare FIGO stage group 1B with 2A–2B, we
notice a significant difference (P-value, 0.009). Also a difference
can be noticed when we compare the group 2A–2B with 3A–4
(P-value, 0.047).
Overall, the group with high-grade FIGO stage (2A or higher)
had significantly lower screen smear compared with the group
with low-grade FIGO stage (1A or 1B) (Po0.001; Table 6a). In the
age groups o29 and/or 463 years, there were no significant
differences between the FIGO stage and having had a screen smear
(P¼ 0.20). Furthermore, we also analysed whether the differences
between FIGO stage and two age groups (29–63 vs o29 and/or
463 years) were significant. The result showed a significant value
at Po0.001 (P-value not shown in Table 6a).
When we analysed FIGO stage of women with a screen smear
(n¼ 100) in relation to their cytology smear result (4BMD, BMD, or
normal) no significant differences were found (Table 6b). However,
women aged 29 and/or463 years showed significantly more cytology
lesions than women aged 29–63 years (Po0.001; data not shown).
We then analysed FIGO stage in relation to screen smear vs
otherwise per-age strata (Figure 2). We noticed a trend of more
severe FIGO stage (FIGO stageX2B) among older women (aged 49
years and older; n¼ 56 out of 89; 62.9%) who had no smear in the
screened period, compared with women who had their smear in
the same period (n¼ 8 out of 33; 24.2%, Po0.001). In addition, we
analysed whether a correlation could be found between the mode
of screening and severe FIGO stage found among women (aged
34–63 years) who had their smear taken in the screened period.
No statistical difference was found (P¼ 0.822; data not shown).
DISCUSSION
Our data show that only 36.7% (105 out of 286) of women
diagnosed with cervical carcinoma in the region of Noord-
Table 6a Women with a smear vs women without a smear in screen smear period, stratified according to FIGO stages, and eligibility for screening
programme (aged 29–60 years, or otherwise)
Cervical carcinoma
Screen smear (i.e., between 1 and 6 years)a Odds ratio
FIGO stage Number Number Percentage within stage (95% CI) Estimate (95% CI) P-value
Aged 29–63 years
Stage 1A 34 18 52.9 (35.1–70.2) 1.39 (0.58–3.30) 0.424 (stage 1A vs 1B)
Stage 1B 95 58 61.1 (50.5–70.9) 0.35 (0.15–0.80) 0.009 (stage 1B vs 2A–2B)
Stages 2A–2B 42 15 35.7 (21.6–52.0) 0.24 (0.41–1.05) 0.047 (stages 2A–2B vs 3A–4)
Stages 3A–4 25 3 12.0 (2.5–31.2) —
Stage unknown 21 5 23.8 (8.2–47.2) —
Total 217 99 45.6 (38.9–52.5) o0.001
Aged o29 or 463 years
Stage 1A 5 1 20.0 (0.5–71.6) 1.00 (0.39–73.56)
Stage 1B 10 2 20.0 (2.5–55.6) 0.57 (0.55–8.18)
Stages 2A–2B 24 3 12.5 (2.7–32.4) —
Stages 3A–4 23 — — —
Stage unknown 7 — — —
Total 69 6 8.7 (3.3–18.0) 0.211
Abbreviations: BMD¼ borderline/mild dyskaryosis; CI¼ confidence interval; FIGO¼ International Federation of Gynaecology and Obstetrics. aInclude smears taken p1 year
before the diagnosis, smears taken 46 years before the diagnosis, and women who never had a smear taken before the diagnosis.
Table 5 Timeliness of abnormal (‘4BMD’ or ‘BMD’) and normal smear
preceding cervical cancer. All smear types (smear and work-up smears)
Cytology Total, n (%) Not delayed, n (%) 95% CI
4BMDa 142 (100) 88 (62.0) 53.5–70.0
BMDb 46 (100) 26 (56.5) 41.1–71.1
Total 188c (100) 114 (60.6) 53.3–67.7
Abbreviations: BMD¼ borderline/mild dyskaryosis; CI¼ confidence interval. aMax-
imum time interval between the first abnormal smear and histologically confirmed
CxCa was 6 months (a longer time interval was considered as delay in the diagnosis).
bMaximum time interval between the first abnormal smear and histologically
confirmed CxCa was 24 months (a longer time interval was considered as delay in
the diagnosis). cIn total, 73 out of 286 women had no smear at all preceding the
diagnosis, thus leaving 213 cases with a smear. A total of 25 out of these 213 women
had only normal cytology (n¼ 23) or information on time was lacking (n¼ 2), leaving
188 cases to analyse. This group consisted of 4BMD or BMD as follows: in the
screen period 15 and 21 women had4BMD and BMD, respectively (Table 3). In the
work-up period group, 75 and 11 women had 4BMD and BMD, respectively.
Furthermore, 41 and 9 women who had a normal smear result in the screen period
had4BMD and BMD, respectively, as work-up smear. Finally, for women who had a
normal smear result in the underscreened period (n¼ 12), 10 women had4BMD as
work-up smear (The remaining two woman had normal smear result again). Another
one and five women had already 4BMD and BMD, respectively, in the
underscreened period (Table 3). This results in a total of 142 4BMD and 46
BMD women (total n¼ 188).
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Holland/Flevoland between 2005 and 2007 were appropriately
screened. If restricted to eligible women for receiving an invitation
for cervical screening (aged 29–63 years), this percentage was
45.6% (99 out of 217). This finding is in agreement with a meta-
analysis study, showing that about 46.2% women had a smear in
the screened period (Spence et al, 2007).
Further analysis showed that 67 out of 105 women (63.8%)
that were ‘screened’ had a normal cytology result (Table 3).
A meta-analysis study had an outcome of 29.3% of women with at
least one normal cytology result in the same period (Spence et al,
2007). However, 48 out of the 67 (74.5%) women in our study
subsequently had abnormal cytology (XBMD) in their work-up
smear, as assumed in previous modelling. Only two women (3.9%)
had again a normal smear result in the work-up smear period.
Even within the context of the limited reproducibility of cytology,
this change from normal cytology to abnormal cytology in women
with subsequent histologically proven cancer is likely to be because
of inappropriate sampling, processing, or erroneous reading of the
cytology.
Furthermore, our data show that 75 out of 217 (34.5%) women
from the eligible age cohorts had been screened within the
screening programme (Table 4) in the appropriate period
preceding the carcinoma diagnosis. From the residual of 142
patients, 29 were possibly ‘screen detected’ within the programme
(13.4%) but were underscreened. The remaining 113 out of 217
eligible women, either did not have cytology p6 years preceding
diagnosis (underscreened period; 40 out of 217; 18.4%), or had
obtained a smear outside the programme (73 out of 217; 33.6%).
These data show that the detected (histologically confirmed)
carcinoma rate was higher among women who had not sufficiently
attended the organised screening (142 out of 217) in the screened
period (65.4 vs 34.6%. Po0.001; Table 4).
The result of timeliness between the first abnormal smear p6
years, preceding the diagnosis and histologically confirmed
diagnosis, showed in 62.0% (95% CI: 53.5–70.0%) no delay in
diagnosis among women with 4BMD as cytology diagnosis and in
56.5% (95% CI: 41.1–71.1%) among women with BMD (P¼ 0.51).
This suggests that significant improvement can be made in both
the compliances with repeats as well as re-dressing delays in
workup.
The correlation between the FIGO stage and women with or
without a cytology smear in screened period showed a difference
for higher stages: a 1.7-fold higher cervical carcinoma stage
(stages 2A–2B) was observed in carcinoma-bearing women
(aged 29–63 years) without cytology history compared with
women at 1B FIGO stage (P¼ 0.009), whereas 1.4-fold higher
cervical carcinoma stage (stages 3A–4) was found among
women without screen smear compared with women with screen
smear and at 2A–2B FIGO stage (P¼ 0.047). Furthermore,
a trend can be seen in the relation between the higher stages
and age of women. The older women (age X49 years) with-
out a smear in the screened period showed significantly
higher FIGO stages compared with older women who had a
smear in the same period (Po0.001). This indicates that non-
screened older women are at higher risk for high-stage cervical
cancer.
In conclusion, our data show that only 34.6% of all eligible
women (aged 29–63 years) had participated in an organised
programmed screening between 1 and p6 years before
diagnosis (95% CI: 28.2–40.9%; Po0.001). Even if women
screened outside the screening programme were included, the
percentage would be 45.6%, which is similar to as reported in
the literature (Spence et al, 2007). Moreover, 67 women had a
normal screen smear, followed by an abnormal smear in either the
next round or in the work-up phase before carcinoma. These
findings demonstrate both programme sensitivity as well as
compliance needs improvement. This may be achieved by
implementing hrHPV testing as the primary screening tool (Cuzick
et al, 2006; Bulkmans et al, 2007; Mayrand et al, 2007; Ronco et al,
2008, 2010).
There are several options to improve the participation rate
in organised screening programme. Hermens et al (2000) have
shown that women are more willing to attend a screening
programme when invitations are sent by their general practitioners
instead by their municipality. Another option to influence the
effectiveness of the screening programme, especially with regard to
timeliness, is increased computerised controls to support physi-
cians in controlling follow-up (Hermens et al, 1999). Finally, we
recently showed that offering self-sampling for hrHPV DNA
testing to non-attendees in the cervical screening programme is
a feasible and effective approach, leading both to increased
coverage and marked detection of CIN2þ /CIN3þ lesions,
particularly in women who did not attend the previous round of
screening (Gok et al, 2010).
Table 6b Results of screen smear stratified according to FIGO stage
4BMD BMD Normal Inadequate
Total
FIGO stage Number (% of column total) Number (% of column total) P-value
Aged 29–63 years
Stage 1A 12 (36.4) 10 (30.3) 11 (33.3) — 33 (18.3) 0.151
Stage 1B 26 (30.2) 15 (17.4) 44 (51.2) 1 (1.2) 86 (47.8) 0.620
Stages 2A–2B 11 (39.3) 4 14.3) 12 (42.9) 1 (3.6) 28 (15.6) 0.346
Stages 3A–4 4 (25.0) 5 (31.3) 6 (37.5) 1 (6.3) 16 (8.9)
Stage unknown 13 (76.5) 1 (5.9) 3 (17.6) — 17 (9.4)
Total 66 (36.7) 35 (19.4) 76 (42.2) 3 (1.7) 180 (100)
Aged o29 or 463 years
Stage 1A 2 (66.7) — 1 (33.3) — 3 (9.1)
Stage 1B 5 (71.4) 2 (28.6) — — 7 (21.2)
Stages 2A–2B 9 (69.2) — 4 (30.8) — 13 (39.4)
Stages 3A–4 4 (100) — — — 4 (12.1)
Stage unknown 5 (83.3) — — 1 (16.7) 6 (18.2)
Total 25 (75.8) 2 (6.1) 5 (15.2) 1 (3.0) 33 (100)
Abbreviations: BMD¼ borderline/mild dyskaryosis; FIGO¼ International Federation of Gynaecology and Obstetrics. Of the 217 total cases in the age group 29–63 years, 37 of
the women were without any smear, leaving 180 cases behind. In 17 cases, FIGO stage could not be assessed. Of the 69 women, in age groupso29 and/or463 years, 36 were
without any preceding smear, leaving 33 cases. In six cases, no FIGO assessment was available.
Cytology preceding carcinoma cases
M Go¨k et al
691
British Journal of Cancer (2011) 104(4), 685 – 692& 2011 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
REFERENCES
Bais AG, van Kemenade FJ, Berkhof J, Verheijen RH, Snijders PJ, Voorhorst F,
Babovic M, van BM, Helmerhorst TJ, Meijer CJ (2007) Human
papillomavirus testing on self-sampled cervicovaginal brushes: an effective
alternative to protect nonresponders in cervical screening programs.
Int J Cancer 120(7): 1505–1510
Bos AB, Rebolj M, Habbema JD, van Ballegooijen M (2006) Nonattendance
is still the main limitation for the effectiveness of screening for cervical
cancer in the Netherlands. Int J Cancer 119(10): 2372–2375
Bos AB, van Ballegooijen M, van Oortmarssen GJ, Habbema JD (2002)
Women who participate in spontaneous screening are not at higher risk
for cervical cancer than women who attend programme screening.
Eur J Cancer 38(6): 827–831
Bulkmans NW, Berkhof J, Rozendaal L, van Kemenade FJ, Boeke AJ, Bulk S,
Voorhorst FJ, Verheijen RH, van GK, BoonME, RuitingaW, van BM, Snijders
PJ, Meijer CJ (2007) Human papillomavirus DNA testing for the detection of
cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a
randomised controlled implementation trial. Lancet 370(9601): 1764–1772
Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de PA, van Krieken JH,
Meijer GA (2007) Pathology databanking and biobanking in The
Netherlands, a central role for PALGA, the nationwide histopathology and
cytopathology data network and archive. Cell Oncol 29(1): 19–24
Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, Szarewski A,
Birembaut P, Kulasingam S, Sasieni P, Iftner T (2006) Overview of the
European and North American studies on HPV testing in primary
cervical cancer screening. Int J Cancer 119(5): 1095–1101
Gok M, Heideman DA, van Kemenade FJ, Berkhof J, Rozendaal L,
Spruyt JW, Voorhorst F, Belien JA, Babovic M, Snijders PJ, Meijer CJ
(2010) HPV testing on self collected cervicovaginal lavage specimens as
screening method for women who do not attend cervical screening:
cohort study. BMJ 340: c1040
Gustafsson L, Ponten J, Zack M, Adami HO (1997) International incidence
rates of invasive cervical cancer after introduction of cytological
screening. Cancer Causes Control 8(5): 755–763
Hermens RP, Hak E, Hulscher ME, Mulder J, Tacken MA, Braspenning JC, Grol
RP (1999) Improving population-based cervical cancer screening in general
practice: effects of a national strategy. Int J Qual Health Care 11(3): 193–200
Hermens RP, Tacken MA, Hulscher ME, Braspenning JC, Grol RP (2000)
Attendance to cervical cancer screening in family practices in The
Netherlands. Prev Med 30(1): 35–42
IARC (2005) Efficacy of screening. In IARC Handbook of Cancer Prevention
Vol. 10, pp 163–199. IARC Press: Lyon
Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferenczy A,
Ratnam S, Coutlee F, Franco EL (2007) Human papillomavirus DNA versus
Papanicolaou screening tests for cervical cancer. N Engl J Med 357(16):
1579–1588
Rebolj M, van BM, Berkers LM, Habbema D (2007) Monitoring a national
cancer prevention program: successful changes in cervical cancer
screening in the Netherlands. Int J Cancer 120(4): 806–812
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Dalla PP,
Del MA, Gillio-Tos A, Minucci D, Naldoni C, Rizzolo R, Schincaglia P,
Volante R, Zappa M, Zorzi M, Cuzick J, Segnan N (2008) Results
at recruitment from a randomized controlled trial comparing
human papillomavirus testing alone with conventional cytology as
the primary cervical cancer screening test. J Natl Cancer Inst 100(7):
492–501
Ronco G, Giorgi-Rossi P, Carozzi F, Confortini M, Palma PD, Del MA,
Ghiringhello B, Girlando S, Gillio-Tos A, De ML, Naldoni C, Pierotti P,
Rizzolo R, Schincaglia P, Zorzi M, Zappa M, Segnan N, Cuzick J (2010)
Efficacy of human papillomavirus testing for the detection of invasive
cervical cancers and cervical intraepithelial neoplasia: a randomised
controlled trial. Lancet Oncol 11(3): 249–257
Sasieni P, Adams J (1999) Effect of screening on cervical cancer mortality in
England and Wales: analysis of trends with an age period cohort model.
BMJ 318(7193): 1244–1245
Spence AR, Goggin P, Franco EL (2007) Process of care failures in invasive
cervical cancer: systematic review and meta-analysis. Prev Med 45(2–3):
93–106
van Ballegooijen M (1998) Effects and Costs of Cervical Cancer Screening.
Erasmus University Rotterdam: Dissertation Rotterdam. Report
van der Graaf Y, Klinkhamer PJ, Vooijs GP (1986) Effect of population
screening for cancer of the uterine cervix in Nijmegen, The Netherlands.
Prev Med 15(6): 582–590
van Oortmarssen GJ, Habbema JD (1991) Epidemiological evidence for
age-dependent regression of pre-invasive cervical cancer. Br J Cancer
64(3): 559–565
Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Borras J,
Parkin DM (2000) International trends in incidence of cervical cancer: II.
Squamous-cell carcinoma. Int J Cancer 86(3): 429–435
Cytology preceding carcinoma cases
M Go¨k et al
692
British Journal of Cancer (2011) 104(4), 685 – 692 & 2011 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
stic
s
